About Genie HT

Genie ® HT was developed specifically for high-throughput environments offering diagnostic testing based on isothermal amplification methods. As with the smaller Genie ® instruments, the Genie ® HT can be fully controlled from its embedded touchscreen and also uses the custom 8-microtube Genie ® Strip. This system was designed to be modular and can be procured with any number of sample blocks installed up to a maximum of 12. Instruments delivered with less than 12 blocks may be upgraded at any time. The Genie ® HT offers full random access with any blocks used at any time.

  • Processes up to 12 strips-of-8 tubes simultaneously
  • Maximum 96 samples in a single run
  • User-selectable number of processing blocks installed
  • Reduce initial investment if working to a budget
  • Additional blocks may be added at any time
  • Complete random access – use any block at any time
  • Stand-alone operation not requiring a computer
  • Controlled from 10.1” high-resolution touchscreen
  • Wired connections to network and USB
  • Wireless WiFi and Bluetooth interfaces
  • Dual-colour fluorescence detection
  • Open platform supporting all isothermal methods


Technical Specifications
Detection methodDual-channel Fluorescence
470 nm excitation, 510-560 nm emission
590 nm excitation, > 620 nm emission
Temperature control methodBlock with 4-zone independent digital PID and heated lid
Temperature control range and accuracyAmbient—100°C, ±0.1°C
Sample number12 x strip of 8 tubes
Sample volume10—150 µl
Size635mm (L) X 434mm (W) X 153mm (H)
Weight18kg / 40lbs
Operating temperature0°C—40°C
Storage temperature20°C—70°C
Environmental protectionIP20
Display / keyboard10.1” High-brightness LCD with multi-touch projective capacitive touch panel (1280 x 800)
Wireless data (1)Bluetooth 2.0
Wireless data (2)Wi-Fi
Wired data1 x USB ‘B’
2 x USB ‘A’
1 x Power in
1 x RJ45 – Network connection
1 x USB ‘A’ – diagnostic port
Power supplyInput: 100-240V AC

Register Genie Instrument

Newsletter Signup
Be The first to hear the latest news from Optigene